Promising diagnostic accuracy of plasma GFAP

Glial fibrillary acidic protein (GFAP) in plasma accurately differentiated patients with Alzheimer’s disease (AD) from healthy controls and thus holds promise as a diagnostic biomarker for AD. This could be a non-invasive and cost-effective method to detect people at risk, early in the neuropathological cascade. GFAP is an intermediate cytoskeletal filament protein of astrocytes and is regarded as a promising non-invasive biomarker for neurodegeneration. It has been shown that GFAP levels are increased in patients with AD compared with healthy controls. Dr Tandis Parvizi (Medical University of Vienna, Austria) examined the utility of GFAP as a biomarker along the AD continuum [1]. In a retrospective, cross-sectional study they included 185 subjects: 44 healthy controls and 141 patients with either subjective cognitive decline (SCD, n=18), mild cognitive impairment (MCI, n=63), or AD (n=60). Concentrations of GFAP in plasma and CSF were quantified using ult...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 18 August, 202118 August, 2021